Adjuvant Therapy(3 vs. 6 Months) With the FOLFOX 4 or XELOX for Stage II or Stage III Colon Cancer

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE3

Total Enrollment

2000 participants

Study Classification

INTERVENTIONAL

Study Start Date

2010-10-31

Study Completion Date

2017-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to compare whether a 3-month treatment is at least not inferior to a 6-month treatment (FOLFOX-4 6 vs. 12 cycles or XELOX 4 cycles vs. 8 cycles) in terms of RFS in patients with high risk stage II or stage III radically resected colon cancer.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study of Xeloda (Capecitabine) Plus Oxaliplatin in Patients With Colon Cancer

NCT00069121

Colorectal Cancer

COMPLETED PHASE3

Adjuvant Chemotherapy in High Risk Stage II Colon Cancer

NCT04303429

Stage II Colon Cancer Adjuvant Chemotherapy

UNKNOWN PHASE3

FOLFOX-4 3months Versus 6 Months and Bevacizumab as Adjuvant Therapy for Patients With Stage II/III Colon Cancer

NCT00646607

Colon Cancer

COMPLETED PHASE3

Combination Chemotherapy for 3 Months or 6 Months in Treating Patients With Stage III Colon Cancer

NCT00958737

Colorectal Cancer

UNKNOWN PHASE3

A Study of Xeloda (Capecitabine) in Patients With Metastatic Colorectal Cancer

NCT00069108

Colorectal Cancer

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Six months of adjuvant chemotherapy with 5-FU and oxaliplatin for patients with stage III colon cancer is the world-wide standard of care, based on the MOSAIC and C-07 trials. However, it leads to significant cost, toxicity, and inconvenience. In particular, the onset of oxaliplatin induced cumulative dose-dependent neuropathies is a significant issue. The ability to maintain efficacy with a reduced duration of therapy would have clear advantage to patients, to providers, and to the health care system.

Multiple large trials in the 1990s demonstrated that the previous standard of 12 months of therapy could be reduced to 6 months. A single small trial with 5-FU alone demonstrated similar outcomes for 3 versus 6 months of therapy. Thus, it is proposed to definitively evaluate the non-inferiority of 3 months of oxaliplatin-based adjuvant chemotherapy versus the current standard of 6 months. The primary endpoint will be disease-free survival (DFS).

It is essential to have sufficient power to eliminate the possibility of clinically meaningful inferiority of 3 months of therapy: a huge number of patients will be necessary. Previous efforts and experience have conclusively demonstrated that in colon cancer, a single, global trial is impractical. Consequently, an international, prospective pooled analysis will be performed, gathering data of independent trials run in different countries, to answer the single primary hypothesis that 3 months of adjuvant therapy with FOLFOX/XELOX is non-inferior to the current standard of 6 months. Among six planned countries, the Greek intergroup will conduct one of these trials.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

CRC

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

FOLFOX 4 - 6months or XELOX -6months

Group Type ACTIVE_COMPARATOR

5-Fluorouracil

Intervention Type DRUG

5-FU 400mg/m2 Bolus and then 22 hours 5-FU 600mg/m2 IV, days 1 \& 2, q2w, for 12 cycles

Leucovorin

Intervention Type DRUG

Leucovorin 200mg/m2 IV in 2 hours, days 1 \& 2, q2w, for 12 cycles

Oxaliplatin

Intervention Type DRUG

Oxaliplatin 85mg/m2 in 2 hours IV, day 1, q2w, for 12 cycles

Capecitabine

Intervention Type DRUG

Capecitabine 1000 mg/m2 X 2 ,days 1-14, q2w, for 8 cycles

Oxaliplatin

Intervention Type DRUG

Oxaliplatin 130 mg/m2 in 2 hours IV, day 1, q2w, for 8 cycles

FOLFOX4 -3months or XELOX -3months

Group Type EXPERIMENTAL

5-Fluorouracil

Intervention Type DRUG

5-FU 400mg/m2 Bolus and then 22 hours 5-FU 600mg/m2 IV, days 1 \& 2, q2w, for 6 cycles

Leucovorin

Intervention Type DRUG

Leucovorin 200mg/m2 IV in 2 hours, days 1 \& 2, q2w, for 6 cycles

Capecitabine

Intervention Type DRUG

Capecitabine 1000 mg/m2 X 2 ,days 1-14, q2w, for 4 cycles

Oxaliplatin

Intervention Type DRUG

Oxaliplatin 130 mg/m2 in 2 hours IV, day 1, q2w, for 4 cycles

Oxaliplatin

Intervention Type DRUG

Oxaliplatin 85mg/m2 in 2 hours IV, day 1, q2w, for 6 cycles

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

5-Fluorouracil

5-FU 400mg/m2 Bolus and then 22 hours 5-FU 600mg/m2 IV, days 1 \& 2, q2w, for 12 cycles

Intervention Type DRUG

Leucovorin

Leucovorin 200mg/m2 IV in 2 hours, days 1 \& 2, q2w, for 12 cycles

Intervention Type DRUG

Oxaliplatin

Oxaliplatin 85mg/m2 in 2 hours IV, day 1, q2w, for 12 cycles

Intervention Type DRUG

Capecitabine

Capecitabine 1000 mg/m2 X 2 ,days 1-14, q2w, for 8 cycles

Intervention Type DRUG

Oxaliplatin

Oxaliplatin 130 mg/m2 in 2 hours IV, day 1, q2w, for 8 cycles

Intervention Type DRUG

5-Fluorouracil

5-FU 400mg/m2 Bolus and then 22 hours 5-FU 600mg/m2 IV, days 1 \& 2, q2w, for 6 cycles

Intervention Type DRUG

Leucovorin

Leucovorin 200mg/m2 IV in 2 hours, days 1 \& 2, q2w, for 6 cycles

Intervention Type DRUG

Capecitabine

Capecitabine 1000 mg/m2 X 2 ,days 1-14, q2w, for 4 cycles

Intervention Type DRUG

Oxaliplatin

Oxaliplatin 130 mg/m2 in 2 hours IV, day 1, q2w, for 4 cycles

Intervention Type DRUG

Oxaliplatin

Oxaliplatin 85mg/m2 in 2 hours IV, day 1, q2w, for 6 cycles

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

5-FU LoHP Xeloda LoHP 5-FU Xeloda LoHP LoHP

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Histologically- - confirmed adenocarcinoma of the colon or rectum stage III or stage with at least one of the follow characteristics T4 tumours, undifferentiated tumor grade \>3, bowel obstruction or perforation, vascular or lymphatic or perineural invasion, \<12 nodes examined, Stage IV.
* Signed written informed consent
* Randomization between 2 -8 weeks after curative surgery
* Age \>18 years
* ECOG performance Status 0-1
* Pretreatment CEA within UNL
* Post-menopausal women or women willing to accept the use of an effective contraception. Pre-menopausal women should have a negative pregnancy test within 72 hours prior to randomization
* Men should also accept to use an effective contraception
* R0 resections

Exclusion Criteria

* Evidence of metastatic disease (including presence of tumor cells in ascites or peritoneal carcinomatosis resected "en bloc")
* Evidence of other malignancies within the last 5 years (other than curatively treated basal cell carcinoma of the skin and/or in situ carcinoma of the cervix)
* No pregnant or lactating women
* Presence of clinically relevant cardiovascular disease
* Presenc of medical history or current evidence of CNS disease
* Presence of peripheral neuropathy ≤ grade 1 (CTCAE v. 3.0)
* History of clinically relevant psychiatric disability, precluding informed consent

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No